Loading data for DRUG — first visit, this takes a few seconds.
Bright Minds Biosciences ... (DRUG)
NasdaqCM: DRUG
· Real-Time Price · USD
77.42
-1.14 (-1.45%)
At close: Aug 24, 2026, 8:00 PM
77.03
+0.00%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
Bright Minds Biosciences Inc. (DRUG) Stock Price, Analysis & Data
-1.45% (1D)
No data available
| Bid | 78.05 |
| Market Cap | 755.77M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.51M |
| 0.09 | |
| -2.06 | |
| n/a | |
| -13.01 | |
| P/B (ttm) | 3.41 |
| P/S (ttm) | n/a |
| Earnings Date | Dec 22, 2026 |
| Ask | 78.23 |
| Volume | 165,854 |
| Avg. Volume (20D) | 300,416 |
| Open | 78.89 |
| Previous Close | 78.56 |
| Day's Range | 77.23 - 79.56 |
| 52-Week Range | 38.00 - 123.75 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About DRUG
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathi...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 22, 2021
Employees 26
Stock Exchange NasdaqCM
Ticker Symbol DRUG
Website https://brightmindsbio.com
Financial Performance
In 2025, Bright Minds Biosciences's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -12.23M, an increase of 336.46%.
Financial StatementsEarnings Surprise
Bright Minds Biosciences has released their quarterly earnings on Aug 14, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.24 exceeds estimates by 1.40, with 67.57% YoY growth.
Bright Minds Biosciences Inc. is scheduled to release its earnings on Dec 22, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2